Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + conatumumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves **carboplatin**, a platinum-based chemotherapy drug that interferes with DNA replication, **conatumumab**, a monoclonal antibody targeting TRAIL-R2 to induce apoptosis in cancer cells, and **paclitaxel**, a taxane that stabilizes microtubules, preventing cell division. The combination is used in cancer treatment, particularly for advanced non-small-cell lung cancer (NSCLC).
02
Targets
MicrotubuleTNFRSF10B (DR5)DNA
Beyond the preview
Go deeper on carboplatin + conatumumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + conatumumab + paclitaxel.